CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 8, 2010
Result type: Reports
Project Number: SR0221-000
Product Line: Reimbursement Review

Generic Name: Maraviroc

Brand Name: Celsentri

Manufacturer: GlaxoSmithKline

Therapeutic Area: HIV infection

Indications: HIV-1, treatment naïve (adult)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 18, 2011

Recommendation Type: Do not list